Gilead to launch generic versions of its hep C drugs

26-09-2018

Gilead to launch generic versions of its hep C drugs

ADragan / iStockphoto.com

Gilead is set to produce cheaper authorised generic (AG) versions of its branded hepatitis C treatments from 2019.


Gilead, Asegua Therapeutics, hepatitis C, drug pricing, patent infringement, Epclusa, Harvoni, generic drug manufacture, US healthcare, branding

LSIPR